Form 4: Seres Therapeutics Executive Matthew R. Henn Granted Stock Options

Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, received stock options for 650,000 shares on February 7, 2025.

Summary

• On February 7, 2025, Matthew R. Henn, the Chief Scientific Officer and EVP of Seres Therapeutics, Inc. (MCRB), was granted stock options.
• The options are for 650,000 shares of common stock.
• The exercise price of the options is $0.782 per share.
• The options vest as to 25% of the shares on February 7, 2026, and the remainder vest in 12 equal quarterly installments thereafter.
• The options expire on February 6, 2035.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to executive compensation. It's neutral in tone and reflects a routine business practice.

Positives

• The granting of stock options to a key executive like the Chief Scientific Officer can be seen as an incentive to drive company performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could potentially incentivize the executive to improve company performance, benefiting shareholders.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates